期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

一种用于流感病毒亚单位疫苗纯度分析的改进方法

An Improved Method of Purity Analysis of Influenza Virus Subunit Vaccine
下载PDF
导出
摘要 目的:在SDS-PAGE方法的基础上建立一种改进方法,用于流感病毒亚单位疫苗中间体的杂质分析。方法:用糖苷酶F对不同亚型的疫苗中间体去糖基化处理后进行SDS-PAGE,与未经去糖基化处理的还原型SDS-PAGE结果进行比较。结果:去糖基化处理消除了血凝素的糖基化对电泳迁移率的影响,从而实现了血凝素亚基和杂质的电泳分离。结论:此方法应用于流感病毒亚单位疫苗中间体的杂质分析,较之常规的还原型SDS-PAGE方法具有更高的分辨力。 Objective： To establish an improved method of impurity analysis based on SDS-PAGE for the inter- mediate of influenza subunit vaccine. Methods： Different types of vaccine intermediates were deglycosylated using PNGase F followed by SDS-PAGE. Deglycosylated and non-deglycosylated samples were analyzed by SDS-PAGE. Results： Deglycosylating eliminate the effects of electrophoretic mobility by haemagglutinin glycosylation. Therefore, subunits of haemagglutinin could be separated from impurities satisfactorily by electrophoresis. Conclusion： This improved method provided a higher resolution in the impurity analysis for influenza subunit vaccine intermediate, in comparison of regular reduced SDS-PAGE.
作者 田文莉 邵铭 祁骥 刘淑珍 谷堃 李长贵 杨旭 李小强
机构地区 天士力金纳生物技术(天津)有限公司 中国食品药品检定研究院
出处 《生物技术通讯》 CAS 2013年第1期98-100,共3页 Letters in Biotechnology
关键词 流感病毒亚单位疫苗 SDS-PAGE 血凝素 糖苷酶F 去糖基化 influenza subunit vaccine SDS-PAGE haemagglutinin PNGase F deglycosylate
分类号 Q503 [生物学—生物化学]
  • 相关文献

参考文献13

  • 1Wang C C,Chen J R,Tseng Y C. Glycans on influen-za hemagglutinin affect receptor binding and immune response[J].{H}Proceedings of the National Academy of Sciences(USA),2009,(43):18137-18142.
  • 2Laver W G,Webster R G. Preparation and immunogenicity of a purified influenza virus haemagglutinin and neuraminidase subunit vaccine[J].{H}Postgraduate Medical Journal,1976,(608):373-378.
  • 3van Damme P,Arnou R,Kafeja F. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influ- enza vaccine using two serological techniques:a randomised comparative study[J].{H}BMC Infectious Diseases,2010.134.
  • 4Gildea S,Arkins S,Walsh C. A comparison of anti-body responses to commercial equine influenza vaccines fol-lowing annual booster vaccination of National Hunt Horssa randomised blind study[J].{H}VACCINE,2011,(22):3917-3922.
  • 5郭元吉;程小雯.流行性感冒病毒及其实验技术[M]{H}北京:中国三峡出版社,199718-19.
  • 6Valentine R C,Isaacs A. The structure of influenza virus fila-ments and spheres[J].{H}Journal of General Microbiology,1957,(01):195-204.
  • 7Choppin P W,Murphy J S,Stoeckenius W. The surface struc-ture of influenza virus filaments[J].{H}VIROLOGY,1961.548-550.
  • 8Maley F,Trimble R B,Tarentino A L. Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases[J].{H}Analytical Biochemistry,1989,(02):195-204.
  • 9Plummer T H Jr,Tarentino A L. Purification of the oligosac-charide-cleaving enzymes of flavobacterium meningosepticum[J].{H}GLYCOBIOLOGY,1991,(03):257-263.
  • 10Anderson M,Cawston T,Cheeseman G G. Molecular-weight estimates of milk-fat-globule-membrane protein-sodium dodec-yl sulphate complexes by electrophoresis in gradient acryl-amide gels[J].{H}BIOCHEMICAL JOURNAL,1974,(03):653-660.

二级参考文献14

  • 1World Health Organization. WHO guidelines on the use of vaccines and antivirals during influenza pandemics [ C ]. WHO / CDS / CSR / RMD/2004. 8. Geneva, Switzerland. 2004.
  • 2Harvey R, wheeler JX, Wallis CL, et al. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1)[J]. Vaccine, 2008, 26(5): 6550-6554.
  • 3Wood JM, Schild GC, Newman RW, et al. An improved single-radial-immunodiffusiou technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines [J]. J Biol Stand, 1977,5 (3) : 237-247.
  • 4Chun S, Li C, Van Domselaar G, et al. Universal antibodies and their applications to the quantitative determination of virtually all Subtypes of the influenza A viral hemagglutinins [J]. Vaccine, 2008, 26 (48) : 6068-6076.
  • 5Kapteyn JC, Saidi MD, Dijkstra R, et al. Haemagglutinin quantification and identification of influenza A&B strains propagated in PER. C6 cells: a novel RP-HPLC method [J]. Vaccine, 2006,24 (16): 3137-3144.
  • 6Garcia-Canas V, Lorbetskie B, Girard M. Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns [J]. J Chromatogr A, 2006,1123 (2) : 225-232.
  • 7Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy [J]. Lancet Infect Dis, 2007, 7 (10): 658-666.
  • 8Luke CJ, Subbarao K. Vaccines for pandemic influenza [J]. Emerg Infec Dis, 2006, 12 (1): 66-72.
  • 9Wood JM, Dunleavy U, Newman RW, et al. The influence of the host cell on standardisation of influenza vaccine potency[J].Dev Biol Stand, 1999, 98: 183-188, 197.
  • 10Kitler ME, Gavinio P, Lavanehy D. Influenza and the work of the World Health Organization [J]. Vaccine, 2002, 20(Suppl 2): S5- S14.

共引文献4

生物技术通讯
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部